Bayside Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Bayside Biosciences's estimated annual revenue is currently $930k per year.
- Bayside Biosciences's estimated revenue per employee is $155,000
Employee Data
- Bayside Biosciences has 6 Employees.
- Bayside Biosciences grew their employee count by -40% last year.
Bayside Biosciences's People
Name | Title | Email/Phone |
---|
Bayside Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Bayside Biosciences?
Located in the heart of Silicon Valley, Bayside BioSciences is a contract provider offering one-stop preclinical services for Biotech and Pharmaceutical industries to facilitate their drug development processes. • Bayside BioSciences is committed to support our clients’ needs in preclinical development. This support includes services in bioanalytic, molecular and cell biology, in vitro and in vivo pharmacology. • We will work closely with our sponsors with great flexibility, to start studies quickly to meet tight timelines, and to adjust study dates and designs as needed to optimize outcomes. • Our capabilities include assay development and in vitro/in vivo pharmacology studies for antibodies, small molecules, siRNAs, proteins, and gene therapy products.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | -40% | N/A |
#2 | $0.6M | 6 | 0% | N/A |
#3 | $0.6M | 6 | N/A | N/A |
#4 | $0.4M | 6 | -40% | N/A |
#5 | $0.4M | 6 | 0% | N/A |